White Paper

Tech sheet: Dr. Reddy's Enzalutamide API Offerings

Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signalling pathway. Enzalutamide has been shown to inhibit androgen binding to androgen receptors competitively and consequently inhibits nuclear translocation of androgen receptors and their interaction with DNA.

Enzalutamide is presently one of the most promising therapy in the prostate cancer space. It is already an off-patent product in some markets and will be a generic in the United States and Europe by 2028. In 2021, the global market for Enzalutamide is 5.6 metric ton ($4.6 billion).

To know more about our API offerings, please read the technical sheet on Enzalutamide by filling the contact from below.

Explore other Whitepapers:

Know More

Email us: api@drreddys.com
+91 40 49002222

Download Now

Please fill the Contact form below in order to view the white paper

* I agree and accept the Privacy Policy and Terms of Use of this website.

Email us: api@drreddys.com | +91 40 49002222

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.